SBI Securities Co. Ltd. Sells 17,449 Shares of Hims & Hers Health, Inc. $HIMS

SBI Securities Co. Ltd. cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 28.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,467 shares of the company’s stock after selling 17,449 shares during the period. SBI Securities Co. Ltd.’s holdings in Hims & Hers Health were worth $2,167,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP lifted its stake in shares of Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after buying an additional 334 shares during the period. Alps Advisors Inc. bought a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $306,000. Cerity Partners LLC acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth approximately $325,000. Xponance Inc. increased its position in shares of Hims & Hers Health by 98.3% during the first quarter. Xponance Inc. now owns 27,960 shares of the company’s stock valued at $826,000 after purchasing an additional 13,857 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in shares of Hims & Hers Health by 239.8% in the first quarter. Mutual of America Capital Management LLC now owns 98,402 shares of the company’s stock valued at $2,908,000 after purchasing an additional 69,441 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,592 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares of the company’s stock, valued at $4,012,354.16. This represents a 14.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Chi sold 900 shares of the firm’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the completion of the sale, the insider owned 291,439 shares of the company’s stock, valued at $16,976,321.75. The trade was a 0.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 712,336 shares of company stock worth $37,611,319. Insiders own 13.71% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $38.99 on Thursday. Hims & Hers Health, Inc. has a 1-year low of $19.15 and a 1-year high of $72.98. The company has a 50 day moving average of $51.10 and a 200-day moving average of $51.26. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market cap of $8.88 billion, a price-to-earnings ratio of 72.20, a PEG ratio of 7.82 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same quarter last year, the company earned $0.32 earnings per share. The firm’s revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial dropped their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $45.27.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.